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Introduction
The incidence of localisation-related epilepsy in the
Dutch population is 7.2/10.000. Eighty per cent of pa-
tients have relatively well-controlled epilepsy [1]. There
are controversies about the definition of relatively well-
controlled epilepsy and refractory epilepsy, particularly
about how to estimate their severity and impact on the
patient’s life. In this study of outpatients from a spe-
cialised epilepsy centre we will refer to “relatively well-
controlled” epilepsy if patients are treated with
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■ Abstract To investigate the ex-
tent and nature of the objective and
subjective cognitive deficits and
health-related quality of life
(HRQOL) in adult outpatients with
relatively well-controlled partial
epilepsy without symptomatic aeti-
ology, who were on carbamazepine
(CBZ) monotherapy. Furthermore,
we studied the influence of the
epilepsy history and medication on
various cognitive functions and the
HRQOL.
56 outpatients (29 male, 27 fe-
male, mean age 41.3 years) with
partial epilepsy were compared
with 56 age-, gender-, and educa-
tion-matched healthy controls.
Patients were tested on attention,
memory, speed of information pro-
cessing, and executive functioning.
Questionnaires aimed at measuring
self-perceived cognitive function-
ing (CFQ) and HRQOL (SF-36) were
administered. Mann Whitney-U
tests were used to compare the two
groups. Linear regression analysis
was performed to identify the
epilepsy and medication-related
factors that are associated with cog-
nitive functioning and HRQOL.
Patients scored lower on mea-
sures of attention (P = 0.03), learn-
ing (P = 0.02) and speed of infor-
mation processing (P = 0.00).
Mental aspects of HRQOL such 
as fatigue were lower (P = 0.00),
whereas physical functioning was
unaffected. These patients also
expressed reductions in mental
functioning as indicated by a low
self-perceived cognitive function-
ing (P = 0.01). Age at onset, dura-
tion of epilepsy, seizure type,
seizure frequency, localisation,
years on CBZ, and CBZ dosage
were not related to cognitive func-
tioning or HRQOL.
Patients with partial epilepsy,
even when able to maintain regular
jobs, have impaired cognition and
HRQOL that cannot be attributed
to their epilepsy history or CBZ
dosage or years of CBZ intake.
Therefore, physicians should be
more aware of their cognition and
HRQOL, in addition to the
antiepileptic drug regime.
■ Key words Partial epilepsy ·
Memory · Attention · Quality of life
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monotherapy, have one seizure per month or less and
have regular jobs. Thanks to improved medical treat-
ment the number of relatively well-controlled patients is
increasing. Considering the fact that they maintain their
regular jobs, seizures of these patients do not appear to
interfere with their social functioning in the work situ-
ation [2].These patients still report more cognitive com-
plaints than healthy controls [3]. It has not been estab-
lished, however, whether their cognitive functioning is
impaired as well. It is thus not clear how widely epilepsy
affects overall functioning in daily life in the subgroup
of patients with relatively well-controlled localisation-
related epilepsy.
In general, patients with localisation-related epilepsy
report low self-perceived cognitive functioning [3], have
cognitive deficits in different domains such as memory,
attention, mental flexibility and motor speed [4], and
perceive their health-related quality of life as lower than
healthy controls on all aspects of mental functioning [5].
However, these studies incorporated patients with a
wide range of aetiologies, medication types, and seizure
frequencies, and maintaining a regular job was not an
inclusion criterion. Therefore, the seizure severity and
the impact on the patient’s life varied in these studies.
The only study into cognition that selected patients on
the basis of their work situation referred to the patients
as “normal epileptics” [2]. In that study, patients with
primary generalised epilepsy and patients who were on
polytherapy in 50 % of the cases, were also included.
Therefore, localisation-related epilepsy or relatively
well-controlled epilepsy was not studied. Moreover, the
control group in this study was not matched in age, gen-
der, and educational level [2]. Therefore, it still remains
unclear if cognitive functioning and HRQOL of the rel-
atively well-controlled patients with localisation-related
epilepsy are impaired.
The objective and self-perceived cognitive deficits
and impaired HRQOL studied in patients with a wide
range of epilepsy characteristics can be associated with
different epilepsy-related factors such as age at onset,
duration, seizure frequency, seizure type, localisation of
the epileptogenic zone and medication-related factors
[6]. Objective cognitive testing of patients with refrac-
tory epilepsy showed that factors such as age at onset [7]
and duration [8] were associated with cognitive func-
tioning. Earlier age at onset and longer duration of
epilepsy are associated with diminished cognitive out-
comes [7, 8]. On the other hand, in the study of “normal
epileptics” age at onset, duration, seizure type, and
seizure frequency could not explain the cognitive im-
pairments [2]. Studies of mixed patient groups, ranging
from relatively well-controlled to refractory epilepsy, re-
vealed that an early age at onset, primary generalised
epilepsies and symptomatic aetiology were associated
with lower intellectual functioning [9, 10]. Furthermore,
in patients with refractory epilepsy memory impair-
ments are associated with localisation of the epilepto-
genic zone in the temporal lobe [11] and might also be
negatively affected by drug treatment [12, 13]. Concern-
ing self-perceived HRQOL, secondarily generalised
seizures (GTCS) and higher seizure frequency have been
negatively associated with HRQOL in mixed patient
groups [14, 15]. In these studies, the seizure frequency of
the patients ranged from no seizures during the last
month to more than one per day, and fewer than half of
these patients were employed full time. The patients’
perceptions of the impact and stigma of their condition
might be associated with impaired HRQOL as well [16].
The purpose of our study was to investigate whether
patients with relatively well-controlled localisation-re-
lated epilepsy who are engaged in normal professional
activities have objective and self-perceived cognitive
deficits and impaired HRQOL compared with matched
healthy controls. Patients who were administered with
CBZ were selected, since this is the first drug of choice in
the majority of patients with partial epilepsy. At the
same time, cognitive side-effects are rarely reported in
CBZ monotherpy treatment [17].
In addition, we studied whether epilepsy-related fac-
tors (age at onset, duration of epilepsy, seizure type,
seizure frequency, and localisation) were associated
with cognitive functioning and HRQOL in the patient
group. Although no effect of medication was expected,
two medication-related factors (years on CBZ and CBZ
dosage) were also evaluated.
Patients and Methods
■ Patients
From January to March 1998 eligible outpatients with localisation-re-
lated epilepsy from three Stichting Epilepsie Instellingen Nederland
outpatient clinics in the Netherlands (Heemstede, Amsterdam, and
Utrecht) were identified in a stepwise fashion.
First, medical chart audits were performed to check inclusion cri-
teria: (1) partial epilepsy; (2) carbamazepine (CBZ) monotherapy; (3)
age from 18 years to 65. Exclusion criteria were: 1) present use of psy-
choactive drugs or antiepileptic drugs other than CBZ; 2) additional
neurological or psychiatric disease according to DSM IV criteria; 3)
severe perceptual deficits; 4) a history of head injury, status epilepti-
cus, neurosurgery, or a neuropsychological evaluation within the last
year. Furthermore, patients were selected if they have relatively well-
controlled epilepsy, which was defined as one seizure per month or
less,and the ability to have a regular job or attend a normal school [2].
This definition is derived from the definition of refractory epilepsy:
patients who have had more than one seizure per month for at least
two years that prevents them from normal social functioning [18].
The eligibility criteria based on information of the medical charts
were met by 148 outpatients. All eligible patients were invited to par-
ticipate by letter by their treating physician.
In the second step, all patients from whom informed consent was
obtained were tested, additionally excluding those patients who had
8) no basic proficiency in the Dutch language, 9) a mental capacity
comparable to an IQ ≤ 80, [19] or 10) mood disorders as indicated by
a score of at least two standard deviations below the mean of healthy
subjects on the Profile of Mood State questionnaire [20], since a high
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prevalence of depression in patients with epilepsy affecting neu-
ropsychological functioning has been reported [21]. Seventy patients
signed the informed consent and were tested.Of these 70 patients, five
patients had an IQ ≤ 80 and four had a mood disorder and thus had
to be excluded. Another five patients were excluded from the 61 pa-
tients who remained, because their seizure frequency had changed in
the meantime and turned out to be more than one per month. Since
this study is part of a large intervention study, all patients, irrespec-
tive of cognitive complaints, were asked to visit the clinic ten times.
Consequently, the major reason for non-participation of the 148 out-
patients was the amount of time asked from each patient.
■ Methods
Standardised testing consisted of neuropsychological tests, a subjec-
tive evaluation of self-perceived HRQOL and self-perceived cognitive
functioning, and a mood-state questionnaire (total duration 90 min-
utes). We successfully matched our patients with healthy controls on
age,gender,and education.The control group was drawn from a large,
cross-sectional study of the biological and psychological determi-
nants of cognitive ageing, the Maastricht Ageing Study [22]. These
healthy controls were recruited from the Registration Network Fam-
ily Practices, a sample frame for research in primary care [23]. Par-
ticipants had no medical conditions known to have an effect on cog-
nition. All neuropsychological tests used in this study were
administered to the healthy controls in the Maastricht Ageing Study,
except for the TAP divided and alertness tasks. The questionnaire
about self-perceived cognitive functioning (CFQ) was also part of the
Maastricht Ageing Study.For the questionnaire about HRQOL,the SF-
36 Health Survey,an individually-matched sample on age,gender,and
education was drawn from other normative data. This questionnaire
was validated among healthy Dutch-speaking residents of the Nether-
lands [24].
Objective Neuropsychological Status.Verbal memory was assessed
with the Auditory Verbal Memory Test (VVLT).Selective attention was
measured with the Stroop Color-Word Test (SCWT) [25]. Measures of
divided attention were derived from the TAP Divided Attention task
[26]. In this test,a visual and an acoustic task are presented simultane-
ously. The visual task consists of crosses that appear in a random con-
figuration in a 4  4 matrix. The subject has to detect whether the
crosses form the corner of the square. In the acoustic task the subject
has to detect an irregularity in a regular sequence of high and low
beeps.Speed of information processing was tested with the TAP Alert-
ness with and without warning task [26]. A reaction time task with
(cued RT) and without (simple RT) a warning signal can be compared.
The test consists of four trials in an ABBA design each containing 20
presentations (A = with out cue, B = with cue). Executive control was
measured with the Catagoric Word Fluency Task (Fluency) [27].
Self-perceived cognitive functioning was assessed using the Cog-
nitive Failure Questionnaire (CFQ), [28] a 25-item self-report ques-
tionnaire that measures failures in daily life in four dimensions: ab-
sent-mindedness, problems with social interactions, difficulties
remembering names and words, and difficulty with orientation. The
total CFQ score ranged from 0 to 100, with higher scores indicating
higher self-perceived cognitive functioning (CFQ).
Self-perceived health-related quality of life was assessed by means
of the Short-Form Health Survey (SF-36) [29]. The SF-36 is a self-re-
port questionnaire that covers the following eight dimensions of
health: physical functioning, role limitations due to physical health
problems, bodily pain, general health perceptions, vitality, social
functioning, role limitations due to emotional problems, and general
mental health. Two higher-order compound scores are computed:
mental compound score (MCS) and physical compound score (PCS).
Raw scores were converted linearly into a 0 to 100 scale, with higher
scores representing better levels of functioning. Normative data for
the healthy Dutch population were available [24]. In a large European
study this questionnaire appeared to be a valid and reliable health sta-
tus measure for descriptive studies in patients with epilepsy [30].
Statistical analysis
Student’s t-tests for independent samples were used to
determine if the neuropsychological performance of the
patients, on the 13 different outcome measures sum-
marised in Table 2, differed from the performance of
healthy controls. The same test was carried out to com-
pare the self-perceived cognitive functioning (CFQ) on
the four dimensions and on the total score of this ques-
tionnaire, between the patients and the healthy controls.
HRQOL of the patients was also compared with healthy
controls on the eight-scaled scores of the SF-36 and the
higher-order compound scores summarised in table 2 as
well.
Linear multiple regression analyses were used to ex-
plore the association between cognitive status and the
epilepsy history variables and medication-related vari-
ables: age at onset, duration, seizure frequency, seizure
type, localisation of the epileptogenic zone, CBZ dosage,
and years on CBZ. The individual effect of each variable
on cognitive status was examined first. Then all vari-
ables that appeared to be influential were examined si-
multaneously in the multiple regression analysis. All of
the nine dependent cognitive variables (see table 2), on
which patients with epilepsy were compared with con-
trols, were examined in the linear multiple regression
analysis. The same procedure was carried out for the
four dimensions of the self-perceived cognitive func-
tioning questionnaire (CFQ) (absent-mindedness,prob-
lems with social interactions, difficulties remembering
names and words, and difficulty with orientation) and
for the HRQOL higher order compound scores (PCS and
MCS).
Results
Table 1 and figure 1 show clinical characteristics of our
sample. The gender distribution of the patients was 29
male and 27 female patients (n = 56). Patients’ level of
education [31] was classified as “low” in seven patients,
as “average” in 27 patients and “high” in 22 patients.
Twenty-three percent of the patients suffered from com-
plex partial seizures. Combination of complex partial
seizures with secondary generalisation accounted for
another 52 %. Simple partial seizures combined with
complex partial seizures or secondary generalisation ac-
counted for the other 25 % of the 56 patients.
The clinical description of the seizures in combina-
tion with the EEG recordings enabled us to classify the
epileptogenic zone: temporal lobe in 22 patients, fronto-
temporal lobe in 15 patients, frontal lobe in eight pa-
tients, other regions in eight, and undetermined in three
patients. Lateralisation was left-sided in 27 patients,
right-sided in 13 patients, and no definite lateralisation
in 16 patients.
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Table 2 shows the results of the neuropsychological
testing. Patients with epilepsy had no difficulty with the
immediate recall of newly presented information (VVLT
Trial 1). The learning capacity of patients with epilepsy
was not limited, in that they did benefit as much as
healthy controls from repeated presentation of the same
material.However,a smaller total amount of information
was stored in the long-term memory of the patients (to-
tal recall).When patients had to recall the information 20
minutes after the initial presentation, they appeared to
retrieve fewer words from long-term memory (delayed
recall) (P = 0.067). These findings demonstrate that pa-
tients with epilepsy not only store less information in
long-term memory, but also that they cannot easily re-
trieve this information at a later date.In addition,their se-
lective attention, measured by the Stroop-Color-Word
Test, showed reduced levels of information-processing
capacity when reading colours (SCWT I). The patients
were more susceptible to irrelevant visual information
than the healthy controls (SCWT interference).
On divided attention tests we found that the patients
had a significantly slower response time than the
healthy controls.The speed of information processing of
cued material was lower in the patients (TAP Alertness
with warning). On the other hand, the patients had no
difficulty with simple tasks like those requiring the gen-
eration of words from specific semantic categories (Flu-
ency Test, P = 0.244). In addition, linear multiple regres-
sion analyses on cognitive outcome revealed that
epilepsy history and medication-related factors were
not associated with the results on cognitive subtests.
Self-perceived cognitive functioning (CFQ), mea-
sured with the total CFQ score, appears to be lower than
the healthy controls (P = 0.000). The patients reported
significantly more difficulties remembering names (P =
0.001) and, finding their way (P = 0.000) than did the
healthy controls. Being absent-minded (P = 0.041) and,
having difficulties with cognitive failures in social inter-
actions (P = 0.041) was not significantly different from
the healthy controls. In addition, no epilepsy or medica-
tion-related factor was associated with self-perceived
cognitive functioning.
Self-perceived health-related quality of life (SF-36)
appeared to be significantly lower on domains con-
cerned with mental functioning (P < 0.005) for the pa-
tients than in the healthy controls.Vitality,measuring fa-
tigue, was the most impaired mental subscale reported
by the patients (P = 0.000). There was no significant dif-
ference between the two groups on the physical sub-
scales (physical functioning and bodily pain).
There was no epilepsy or medication-related factor
that could contribute significantly to health-related
quality of life, measured with MCS or PCS.
Table 1 Clinical characteristics of 56 outpatients with partial epilepsy on CBZ
monotherapy
Variables Mean±SD Range
Age (yrs) 41.3±10.8 21.9–63.5
Age at onset of epilepsy (yrs) 24.5±14.3 0–58
Duration of epilepsy (yrs) 17.9±12.7 1–54
Duration CBZ therapy (yrs) 9.2±6 2–26
Serum level CBZ (mg/l) 6.8±2.2 3–13.1
Dosage (mg) 600±300 100–1600
Fig. 1 Seizure frequency of 56 patients with relatively well-controlled partial
epilepsy
* sf = seizure free
Table 2 Neuropsychological test scores and scores on subscales of the SF-36,
measuring health-related quality of life (HRQOL) of patients with epilepsy and
healthy controls
Variables Patients with Healthy aP <
Epilepsy Controls
(n = 56) (n = 56)
Mean±SD Mean±SD
Neuropsychological test scores:
Memory (VVLT):
Trial 1 (nc) 5.7±1.9 6.3±1.7 NS
Total Recall (nc) 43.4±9.8 49.1±9.1 0.002
Delayed recall (nc) 9.1±2.8 10.1±3.0 NS
Attention (SCWT):
Card I (s) 48.3±12.1 39.9±5.5 0.000
Interference (s) 66.7±27.9 85.0±34.6 0.003
TAP Divided Attention (ms) 728.0±75.8 647.0±69.4 0.000
Speed of information processing:
TAP Alertness with warning (ms) 256±49.7 213±55.7 0.000
TAP Alertness without warning (ms) 264±86.2 224±80.0 NS
Executive function:
Fluency (nc) 23.6±6.6 25.0±6.8 NS
HRQOL scores (SF-36)*:
Physical functioning 90.4±11.8 90.8±11.5 NS
Role physical 71.4±33.8 87.2±29.1 0.009
Bodily pain 76.0±22.4 78.2±21.2 NS
General Health 70.2±18.5 80.2±16.8 NS
Vitality 62.8±15.9 75.4±17.3 0.000
Social Functioning 81.4±18.1 90.1±16.4 0.009
Role emotional 76.7±35.5 91.2±25.6 NS
Mental Health 75.7±15.8 80.8±17.3 NS
Physical Compound Score (PCS) 50.1±7.2 52.0±7.9 NS
Mental Compound Score (MCS) 49.4±9.0 54.3±9.3 NS
See methods for explanation of abbreviations of variables. (s): seconds, (ms): mil-
liseconds, (nc): number of correct responses. *Healthy controls for the SF-36 were
derived from a different sample than the sample for the neuropsychological tests.
Higher scores indicate better HRQOL.
a values of Student t-test comparisons between patients with epilepsy and healthy
age, gender, and education matched controls.
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Discussion
We studied adult outpatients with partial epilepsy,
without symptomatic aetiology, on carbamazepine
monotherapy. Since all these patients worked in a regu-
lar setting or attended regular schools, despite the fact
that 50 % still had seizures, we expected that their
epilepsy severity would have a mild effect on their func-
tioning in the work situation. Considering cognitive
functioning, we found that these relatively well-con-
trolled patients performed significantly worse on mem-
ory, selective and divided attention functions, and speed
of information processing than the matched healthy
controls. The diminished speed of information process-
ing we found has also been established by pharmaco-
logical studies and might be due to medication [32].
REM sleep deprivation for example, caused by CBZ,
might have affected cognitive performance, although
the magnitude of this effect compared with other
epilepsy-related characteristics remains controversial
[33]. In accordance with other pharmacological studies
on CBZ [34],we did not find an association between CBZ
dosage or years of CBZ intake and impaired cognitive
performance in our study.
Self-perceived cognitive functioning appears to be
lower in adults with relatively well-controlled epilepsy
than in healthy controls. A study by Corcoran and
Thompson [35] revealed that patients with a late age at
onset of epilepsy complained more about cognition.
They suggested that patients might have more difficul-
ties developing behavioural strategies that circumvent
impaired functions at a later point in life. However, we
did not find a relationship between age at onset and self-
perceived cognitive functioning. Since seizure fre-
quency, aetiology and medication-related factors were
not reported in the study by Corcoran, a comparison
with our subgroup was not possible.
Self-perceived health-related quality of life was
poorer in patients with relatively well-controlled
epilepsy than in matched healthy controls, especially on
the subscales measuring mental functioning, whereas
the physical subscales were unaffected. This finding is in
line with the results of a large European study in which
the SF-36 was used as well [30]. However, again in this
study the epilepsy related factors varied greatly among
the patients, and only 46 % were working in a normal
setting. The most impaired subscale in this study was
“vitality” which is an index for fatigue. Further research
is needed to investigate whether their self-perceived fa-
tigue might have been caused by the extra effort needed
to compensate for their impaired cognitive functioning,
while working in normal settings. Replication of this
study is needed with patients from a general hospital,
since the patients in this study were selected from a spe-
cialised epilepsy center. Therefore, data can not be gen-
eralised to the general epilepsy population.
Another objective of this study was to explain the re-
sults in terms of factors that contribute to the cognitive
impairments, impaired self-perceived cognitive func-
tioning and impaired HRQOL. Unexpectedly, no signif-
icant relationship was established between the specific
factors age at onset, seizure type, duration of epilepsy,
seizure frequency, localisation, CBZ dosage, and years
on CBZ on the one hand, and objective cognitive func-
tioning, self-perceived cognitive functioning or HRQOL
on the other hand [2]. This finding that the investigated
factors cannot clarify the cognitive impairments is sup-
ported by studies in newly-diagnosed patients with par-
tial epilepsy.These patients show cognitive impairments
as well, despite the fact that factors such as anti-epilep-
tic medication, age at onset of epilepsy, duration of
epilepsy, and frequency of seizures are excluded. In this
study, the causes for their epilepsy, either through bio-
chemical processes or through the underlying neuronal
damage, appear to be the most important factor leading
to cognitive impairments. Concerning self-perceived
health-related quality of life the patients’ negative ob-
servation of themselves and of their epilepsy together
with a different attitude from the social context affects
overall well-being and can better explain the observed
differences with healthy controls [36]. Ryan demon-
strated that perceptions of stigma in epilepsy patients
were more strongly influenced by self-perceptions than
by the objective facts of epilepsy [16].
It remains unclear whether the underlying cause for
their epilepsy, the different attitudes towards these pa-
tients in a social context, or a combination of both can
explain the impaired cognitive functioning and im-
paired HRQOL.
Moreover, a nonspecific effect of having a chronic ill-
ness can not be excluded and therefore, a comparison
with a patient group without a CNS disease might have
been a valid additional control group. Loiseau [2] incor-
porated a control group of patients without a CNS dis-
ease and, although there are differences from our study
design, memory impairments could not be attributed to
a nonspecific effect of having a chronic disease.
In conclusion, our results show that relatively well-
controlled patients with partial epilepsy do have cogni-
tive deficits and perceive their cognitive functioning as
low compared with healthy controls.We determined that
their HRQOL of mental functioning is significantly
lower than healthy controls’ HRQOL. However, most
epilepsy-related factors known to alter cognitive per-
formances or HRQOL in patients with refractory
epilepsy could not be identified in this subgroup of pa-
tients.
In this subgroup of patients alterations in the seizure
history,and consequently changes in CBZ dosage,do not
seem to contribute to impaired cognition or HRQOL.
Nonetheless, physicians should also be aware of the ob-
jective cognitive deficits, and the lower self-perceived
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HRQOL and cognitive functioning, in these relatively
well-controlled patients with localisation-related
epilepsy. Subsequently, physicians can encourage pa-
tients to participate in cognitive rehabilitation programs.
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